Berenberg Bank analyst Iris Long maintained a Buy rating on Omnicell (NASDAQ:OMCL) on Friday, setting a price target of $173, which is approximately 21.97% above the present share price of $141.84.
Long expects Omnicell to post earnings per share (EPS) of $0.33 for the third quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Omnicell, with an average price target of $169.2.
The analysts price targets range from a high of $188 to a low of $146.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $251.84 million and a net profit of $19.61 million. The company's market cap is $6.13 billion.
According to TipRanks.com, Berenberg Bank analyst Iris Long is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 12.3% and a 66.67% success rate.
Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence; platform and interoperability; central pharmacy dispensing; medication adherence; population health; and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Mountain View, CA.